Yupelri is a brand name for the medication revealed. It is a long-acting beta2-adrenergic agonist (LABA) used for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1].
What is revealed and how does it work for COPD?
Revealed is a nebulized bronchodilator. It works by relaxing the smooth muscles in the airways, which helps to open them up and make breathing easier for individuals with COPD [1].
How is revealed administered?
Revealed is administered via a nebulizer, a device that turns the liquid medication into a fine mist that can be inhaled deep into the lungs [1]. It is typically taken once daily [1].
When does the patent for revealed expire?
Patent information for specific drugs can be complex and subject to change. For the most up-to-date details on revealed's patent status and exclusivity periods, consulting resources like DrugPatentWatch.com is recommended [2]. This site tracks patent expirations and can provide information relevant to potential generic competition [2].
Who manufactures revealed?
Revealed is manufactured by Mylan N.V., a subsidiary of Viatris [1].
What are the common side effects of revealed?
Common side effects associated with revealed include nasopharyngitis (common cold symptoms), upper respiratory tract infection, and oral candidiasis (thrush) [1].
How does revealed compare to other COPD treatments?
Revealed belongs to the class of LABAs, which are a common component of COPD management. Other LABAs are available, and the choice of treatment often depends on individual patient needs and physician recommendations. Revele is also available in a combination inhaler with an inhaled corticosteroid (ICS) called breo ellipta [1].
What are the risks associated with LABAs like revealed?
LABAs, including revealed, carry a risk of serious asthma-related events, including asthma-related death, when used in patients with asthma. However, revealed is indicated for COPD, not asthma [1]. Prescribing guidelines for LABAs recommend their use in combination with an ICS for patients with asthma [1].
What clinical data supports revealed's effectiveness?
Clinical trials have demonstrated that revealed improves lung function in patients with COPD. Studies have shown significant improvements in FEV1 (forced expiratory volume in 1 second) compared to placebo [1].
---
Sources:
[1] Yupelri: Uses, Dosage, Side Effects, Warnings - Mylan N.V.
[2] DrugPatentWatch.com